.Planet Health Association. Excessive weight and over weight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2024 ).
Non-Communicable Illness Threat Factor Partnership. Worldwide fads in underweight and also obesity from 1990 to 2022: a pooled analysis of 3663 population-representative research studies with 222 million kids, youngsters, and grownups. Lancet 403, 1027u00e2 $ “1050 (2024 ).
Articleu00c2.Google.com Scholaru00c2.Worldwide Concern Condition Partners. Global, regional, and also national worry of diabetic issues from 1990 to 2021, with forecasts of frequency to 2050: a methodical evaluation for the International Worry of Illness Research Study 2021. Lancet 402, 203u00e2 $ “234 (2023 ).
Articleu00c2.Google.com Scholaru00c2.Kovesdy, C. P., Furth, S. L.
& Zoccali, C & Globe Renal Time Steerage Board. Obesity as well as renal health condition: hidden consequences of the prevalent. Renal Int.
91, 260u00e2 $ “262 (2017 ). Garofalo, C. et al.
A step-by-step assessment and meta-analysis advises excessive weight predicts onset of severe kidney disease in the standard populace. Kidney Int. 91, 1224u00e2 $ “1235 (2017 ).
Articleu00c2.Google.com Scholaru00c2.Jiang, Z. et cetera. Being overweight and persistent kidney ailment.
Am. J. Physiol.
Endocrinol. Metab. 324, E24u00e2 $ “E41 (2023 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Hall, J. E., will Carmo, J. M., da Silva, A.
A., Wang, Z. & Venue, M. E.
Excessive weight, kidney dysfunction as well as high blood pressure: mechanistic links. Nat. Rev.
Nephrol. 15, 367u00e2 $ “385 (2019 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Kidney Health Condition: Improving Global End Results CKD The Office Team.
KDIGO 2024 Medical Practice Rule for the examination and monitoring of constant renal condition. Kidney Int. 105, S117u00e2 $ “S314 (2024 ).
Articleu00c2.Google.com Scholaru00c2.Renal Ailment: Improving Worldwide End Results Diabetes Mellitus Workplace Team. KDIGO 2022 Medical Method Rule for diabetic issues control in persistent renal disease. Renal Int.
102, S1u00e2 $ “S127 (2022 ). Articleu00c2.Google.com Scholaru00c2.Oshima, M. et al.
Early modification in albuminuria along with canagliflozin predicts kidney and also heart end results: a message hoc analysis from the CREDENCE trial. J. Am.
Soc. Nephrol. 31, 2925u00e2 $ “2936 (2020 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.de Zeeuw, D. et al. Proteinuria, an aim at for renoprotection in individuals along with kind 2 diabetic person nephropathy: lessons coming from RENAAL.
Kidney Int. 65, 2309u00e2 $ “2320 (2004 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. et cetera. Is actually a decrease in albuminuria associated with kidney as well as cardio security?
A blog post hoc analysis of the ALTITUDE test. Diabetes mellitus Obes. Metab.
18, 169u00e2 $ “177 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Michos, E. D., Bakris, G.
L., Rodbard, H. W. & Tuttle, K.
R. Glucagon-like peptide-1 receptor agonists in diabetic kidney condition: an assessment of their kidney as well as heart defense. Are actually.
J. Prev. Cardiol.
14, 100502 (2023 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Muskiet, M. H.
A. et al. GLP-1 and the renal: from anatomy to pharmacology and also end results in diabetes.
Nat. Rev. Nephrol.
13, 605u00e2 $ “628 (2017 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Marso, S. P.
et al. Semaglutide as well as cardio end results in clients along with kind 2 diabetes. N.
Engl. J. Med.
375, 1834u00e2 $ “1844 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Lincoff, A. M.
et cetera. Semaglutide as well as cardiovascular results in obesity without diabetic issues. N.
Engl. J. Medication.
389, 2221u00e2 $ “2232 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Perkovic, V. et cetera.
Effects of semaglutide on persistent renal condition in people along with style 2 diabetes mellitus. N. Engl.
J. Med. 391, 109u00e2 $ “121 (2024 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Colhoun, H. M. et al.
Lasting renal results of semaglutide in excessive weight and heart disease in the SELECT trial. Nat. Med.
30, 2058u00e2 $ “2066 (2024 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et cetera. Impacts of semaglutide on albuminuria and also kidney function in individuals along with over weight or excessive weight with or even without style 2 diabetes mellitus: prolegomenous evaluation coming from the action 1, 2, as well as 3 tests.
Diabetes Treatment 46, 801u00e2 $ “810 (2023 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Medicine Man, A. M.
et cetera. Impact of the glucagon-like peptide-1 receptor agonists semaglutide and also liraglutide on renal outcomes in people with type 2 diabetes: pooled review of SUSTAIN 6 and also LEADER. Circulation 145, 575u00e2 $ “585 (2022 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Apperloo, E. M. et al.
Effect of semaglutide on kidney functionality throughout different levels of baseline HbA1c, high blood pressure, body system weight as well as albuminuria in SUSTAIN 6 and also PIONEER 6. Nephrol. Dial.
Transplant. gfae150 (2024 ). Tuttle, K.
R. et cetera. Dulaglutide versus insulin glargine in clients with style 2 diabetes and moderate-to-severe constant renal condition (AWARD-7): a multicentre, open-label, randomised test.
Lancet Diabetes Endocrinol. 6, 605u00e2 $ “617 (2018 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et al.
Adjustment in albuminuria as a surrogate endpoint for development of renal ailment: a meta-analysis of therapy effects in randomised medical trials. Lancet Diabetes Endocrinol. 7, 128u00e2 $ “139 (2019 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Mann, J. F. E.
et al. Results of semaglutide along with and without associated with SGLT2 inhibitor make use of in attendees with kind 2 diabetes and also severe renal ailment in the circulation test. Nat.
Med. https://doi.org/10.1038/s41591-024-03133-0 (2024 ). Neuen, B.
L. et al. Cardiovascular, kidney and security outcomes along with GLP-1 receptor agonists alone and in combo with SGLT2 preventions in style 2 diabetic issues: an organized evaluation as well as meta-analysis.
Blood circulation https://doi.org/10.1161/CIRCULATIONAHA.124.071689 (2024 ). Apperloo, E. M.
et cetera. Efficiency and also safety and security of SGLT2 inhibitors along with as well as without glucagon-like peptide 1 receptor agonists: a SMART-C collective meta-analysis of randomised measured trials. Lancet Diabetes Mellitus Endocrinol.
12, 545u00e2 $ “557 (2024 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Results of tirzepatide versus the hormone insulin glargine on kidney outcomes in style 2 diabetic issues in the SURPASS-4 test: post-hoc study of an open-label, randomised, period 3 trial.
Lancet Diabetes Mellitus Endocrinol. 10, 774u00e2 $ “785 (2022 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Tuttle, K.
R. et cetera. Body system body weight and also eGFR in the course of dulaglutide therapy in kind 2 diabetes mellitus and also moderate-to-severe constant renal ailment (AWARD-7).
Diabetes mellitus Obes. Metab. 21, 1493u00e2 $ “1497 (2019 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J. L.
et al. Results of tirzepatide versus the hormone insulin glargine on cystatin c-based kidney feature: a SURPASS-4 article hoc evaluation. Diabetes mellitus Care 46, 1501u00e2 $ “1506 (2023 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Diabetic Issues Care (American Diabetic issues Organization, accessed 1 September 2024) https://diabetesjournals.org/diabetes/issue/73/Supplement_1Li, K. et cetera. Impacts of bariatric surgical operation on renal functionality in overweight people: a step-by-step review and meta study.
PLoS ONE 11, e0163907 (2016 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Bilha, S. C.
et cetera. The impacts of bariatric surgical treatment on kidney end results: a methodical examine and also meta-analysis. Obes.
Surg. 28, 3815u00e2 $ “3833 (2018 ). Articleu00c2.Google.com Scholaru00c2.Clerte, M.
et cetera. The measured glomerular filtration fee (mGFR) before and also 6 months after bariatric surgical procedure: a captain research. Nephrol.
Ther. 13, 160u00e2 $ “167 (2017 ). Articleu00c2.Google Scholaru00c2.Fawaz, S.
et cetera. Adiponectin lowers glomerular endothelial glycocalyx disturbance and also rejuvenates glomerular barrier feature in a mouse version of type 2 diabetes. Diabetes mellitus 73, 964u00e2 $ “976 (2024 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Sasson, A. N. & Cherney, D.
Z. Kidney hyperfiltration related to diabetic issues mellitus as well as excessive weight in individual health condition. World J.
Diabetes 3, 1u00e2 $ “6 (2012 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Chagnac, A. & Friedman, A.
N. Gauging albuminuria in individuals with obesity: risks of the urinary albumin-creatinine ratio. Renal Med.
6, 100804 (2024 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Wilding, J. P.
H. et cetera. Once-weekly semaglutide in adults with overweight or excessive weight.
N. Engl. J.
Med. 384, 989u00e2 $ “1002 (2021 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Levey, A.
S. et cetera. A more exact technique to predict glomerular purification percentage from cream creatinine: a brand new prediction formula.
Modification of Diet Regimen in Renal Health Condition Study Group. Ann. Trainee.
Med. 130, 461u00e2 $ “470 (1999 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Stevens, J.
et cetera. UHPLC-MS/MS technique for iohexol determination in human EDTA and also lithium-heparin plasma televisions, human urine and in goat- and pig EDTA blood. Bioanalysis 12, 981u00e2 $ “990 (2020 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K. R. et al.
Efficacy and also safety and security of aldosterone synthase obstacle along with and without empagliflozin for persistent renal illness: a randomised, handled, phase 2 trial. Lancet 403, 379u00e2 $ “390 (2024 ). Articleu00c2.CASu00c2.Google Scholaru00c2.de Zeeuw, D.
et al. Effectiveness of an unfamiliar prevention of vascular adhesion protein-1 in decreasing albuminuria in patients along with diabetic person kidney illness (CD): a randomised, placebo-controlled, phase 2 test. Lancet Diabetes Endocrinol.
6, 925u00e2 $ “933 (2018 ). Articleu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Zibotentan in mix with dapagliflozin compared to dapagliflozin in clients with chronic renal condition (ZENITH-CKD): a multicentre, randomised, active-controlled, stage 2b, clinical test.
Lancet 402, 2004u00e2 $ “2017 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et cetera. Impact of avenciguat on albuminuria in clients with CKD: 2 randomized placebo-controlled tests.
J. Am. Soc.
Nephrol. 25, 1227u00e2 $ “1239 (2024 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et al.
Sparsentan in individuals with IgA nephropathy: a prespecified meantime study from a randomised, double-blind, active-controlled clinical trial. Lancet 401, 1584u00e2 $ “1594 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.